Sentence examples for on background therapy from inspiring English sources

This was seen in this study for subjects on background therapy with insulin or a sulphonylurea agent, in whom both canagliflozin doses were associated with the expected higher incidences of hypoglycaemia relative to placebo.

With the addition of so many new agents to our therapeutic armamentarium, it is no surprise that it is hard to find patients for enrollment in RCTs in RA, especially those on background therapy yet with sufficiently active disease.

This meta-analysis included any arm of RCTs on the efficacy of DPP-4 inhibitors in participants who were either drug naïve, or on background therapy with metformin or other oral agents.

Also, patients may have had high disease activity and were selected after exhibiting a flare of symptoms upon withdrawal of previous NSAID therapy, indicating a proclivity to respond to therapy with etoricoxib while on background therapy.

Results of a Phase II, 43-patient, placebo-controlled, double-blind study, where patients were randomized in a 3 : 1 ratio receiving selexipag (200  μg–800  μg twice-daily) or placebo on background therapy with an endothelin-receptor antagonist or phosphodiesterase type-5 inhibitor or both, showed a statistically significant reduction in pulmonary vascular resistance (primary end point) [ 60].

Their basic design involves administering the test agent of interest to a population of patients who are no longer achieving optimal glucose control on a pre-existing regimen of background therapy.

19 As noted previously, while alogliptin has been studied in combination and as add-on to a variety of background therapies, clinical trial data with alogliptin in combination with metformin and pioglitazone are highlighted herein.

A persistent concern has been whether patients enrolled in these add-on trials had previously responded to background therapy.

These patients were in New York Heart Association Functional Class 4 and on optimal background therapy including parenteral prostanoid therapy.

Simulations predict a slightly greater maximum percent reduction in LDL cholesterol (LDLc) when anti-PCSK9 is administered on statin background therapy compared to as a monotherapy.

In the 26-week LEAD-5 trial, liraglutide produced a greater reduction in HbA1c level and body weight than insulin glargine on a background therapy of metformin and glimepiride.